Loading...
Founded in 2017
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
Founded
2017
Employees
Funding
Lori Hu
Board Director